Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,738Revenue (TTM) $M469Net Margin (%)13.2Altman Z-Score8.4
Enterprise Value $M1,647EPS (TTM) $1.9Operating Margin %21.9Piotroski F-Score7
P/E(ttm)28.7Beneish M-Score-2.9Pre-tax Margin (%)21.9Higher ROA y-yN
Price/Book4.810-y EBITDA Growth Rate %8.0Quick Ratio1.8Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %18.4Current Ratio3.7Lower Leverage y-yY
Price/Free Cash Flow32.4y-y EBITDA Growth Rate %18.9ROA % (ttm)11.7Higher Current Ratio y-yY
Dividend Yield %--PEG1.5ROE % (ttm)18.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M32.2ROIC % (ttm)24.3Gross Margin Increase y-yY

Gurus Latest Trades with CBM

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
CBMThird Avenue Management 2016-09-30 Add0.01%$42.83 - $58.85
$ 54.0511%Add 9.47%83,939
CBMThird Avenue Management 2016-03-31 Buy 0.13%$31.12 - $47.09
$ 54.0537%New holding76,681
CBMJoel Greenblatt 2016-03-31 Sold Out -0.06%$31.12 - $47.09
$ 54.0537%Sold Out0
CBMJoel Greenblatt 2015-12-31 Reduce-0.01%$40.43 - $53.63
$ 54.0512%Reduce -19.35%110,565
CBMJoel Greenblatt 2015-09-30 Reduce-0.05%$39.57 - $53.82
$ 54.0516%Reduce -48.98%137,090
CBMJoel Greenblatt 2015-06-30 Add0.08%$35.71 - $46.24
$ 54.0531%Add 341.54%268,701
CBMJoel Greenblatt 2015-03-31 Reduce$21.34 - $39.63
$ 54.0583%Reduce -22.55%60,855
CBMJoel Greenblatt 2014-12-31 Buy 0.01%$16.33 - $24.12
$ 54.05154%New holding78,575
CBMJoel Greenblatt 2013-03-31 Sold Out -0.09%$11.27 - $12.79
$ 54.05353%Sold Out0
CBMJoel Greenblatt 2012-12-31 Buy 0.09%$9.34 - $13.96
$ 54.05375%New holding142,352
CBMJoel Greenblatt 2012-09-30 Sold Out -0.02%$9.01 - $13.01
$ 54.05389%Sold Out0
CBMJoel Greenblatt 2012-06-30 Buy 0.02%$5.96 - $9.16
$ 54.05664%New holding30,208
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CBM is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

CBM: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Cavanagh ShawnEVP & COO 2016-12-14Sell30,000$53.580.88view
SARGEN GREGORYExecutive Vice President & CFO 2016-11-11Sell22,500$52.023.9view
KLOSK STEVEN MPresident & CEO 2016-11-09Sell50,000$50.876.25view
KORB WILLIAM BDirector 2016-07-11Sell3,420$55-1.73view
KORB WILLIAM BDirector 2016-06-08Sell4,142$52.473.01view
KORB WILLIAM BDirector 2016-06-01Sell8,000$51.065.86view
KLOSK STEVEN MPresident & CEO 2016-05-09Sell14,005$4910.31view
KLOSK STEVEN MPresident & CEO 2016-05-05Sell16,430$49.1310.01view
KORB WILLIAM BDirector 2016-05-03Sell8,000$49.0910.1view
KLOSK STEVEN MPresident & CEO 2016-03-16Sell19,565$4131.83view

Quarterly/Annual Reports about CBM:

News about CBM:

Articles On GuruFocus.com
Third Avenue Comments on Cambrex Corp May 27 2016 
Chip Rewey's Third Avenue Small-Cap Value Fund 2nd Quarter Commentary May 27 2016 
Royce Smaller-Companies Growth Fund Annual Letter Mar 19 2016 
Royce Smaller-Companies Growth Fund Shareholder Letter Sep 20 2015 
Cambrex Corp. Reports Operating Results (10-Q) Aug 04 2010 
Cambrex Corp. Reports Operating Results (10-Q) May 05 2010 
Does Cambrex Corporation Have Earnings Persistence? Apr 28 2010 
Cambrex Corp. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
Merck KGaA Expands Distribution Deal with Roche (revised) Jan 17 2017
Momenta (MNTA) to Receive $50M Under CSL Collaboration Jan 06 2017
Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication Jan 06 2017
Zacks.com featured highlights: Braskem, Cambrex, Daqo New Energy, State National Companies and... Jan 06 2017
Genocea Stock Up on Positive Genital Herpes Infections Data Jan 06 2017
Biogen Licenses Amunix's XTEN Technology for Factor IX Drug Jan 06 2017
Amgen's Repatha Wins Over Sanofi & Regeneron's Praluent Jan 06 2017
Arena, Eisai Modify Marketing & Supply Agreement for Belviq Jan 05 2017
Spark Therapeutics Gets $15M Milestone Payment from Pfizer Jan 05 2017
Ocular (OCUL) Reports Positive Phase III Data on Eye Drug Jan 05 2017
Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III Jan 05 2017
Top 5 Stocks with Solid Net Profit Margin Jan 05 2017
Allergan (AGN) Liletta sNDA Accepted for Review in the U.S. Jan 05 2017
Bayer's sNDA for Stivarga Granted Priority Review in the U.S. Jan 05 2017
Get Ready To Be Surprised This Earnings Season Jan 04 2017
Clovis Declares Pricing of Upsized Offering of Common Stock Jan 04 2017
Eli Lilly Acquires Boehringer Ingelheim's Pet Vaccines Unit Jan 04 2017
Allergan Natrelle Inspira Breast Implants Approved in the U.S. Jan 04 2017
Inotek (ITEK) Down on Poor Phase III Glaucoma Drug Data Jan 04 2017
Cambrex Appoints Tom Vadaketh as Executive Vice President and Chief Financial Officer Jan 04 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)